[212Pb] PSV 359 - Perspective Therapeutics
Alternative Names: [212Pb]Pb-PSV359 - Perspective Therapeutics; Lead-212 PSV359 - Perspective Therapeutics; PSV359 - Perspective TherapeuticsLatest Information Update: 03 Feb 2025
Price :
$50 *
At a glance
- Originator Perspective Therapeutics
- Class Antineoplastics; Lead radioisotopes; Peptides; Radiopharmaceuticals
- Mechanism of Action Ionising radiation emitters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 23 Oct 2024 Pharmacokinetics data from a preclinical trial in Solid tumours released by Perspective Therapeutics
- 12 Aug 2024 Perspective Therapeutics plans to file an IND application with the FDA in USA for Solid tumours in late 2024
- 12 Aug 2024 Pharmacodynamics data from a preclinical trial in Solid tumours released by Perspective Therapeutics